Saturday 17 October 2026 Export BNTX’s income statement to Excel — free account

BioNTech SE Sponsored ADR

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.

87.57 2.63 −2.92%

Follow BNTX

Alert me

Market cap: $22.7B
P/E: 0.0×
Fwd P/E: −17.4×
Dividend yield: —
F-score: 4/9
Altman Z: n/a
Beneish M: −2.74
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 81.32

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	1	—	—	—	—	9	4

Insider Ownership 1.27%

Capital & Financial Ratios $m

Market Cap 22,660.00

Revenue 3,019.37

Net Income (1,885.05)

Free Cash Flow 500.72

Net Debt (16,815.78)

Current Ratio 7.85

Debt/Equity 0.02

P/E ratio 0.00

Fwd P/E (17.40)

P/S ratio 7.35

P/B ratio 1.07

Past 5Y EPS Growth —

This Y EPS Growth (15.61%)

Next Y EPS Growth (2.96%)

Next Y revenue growth (38.16%)

Next 5Y EPS Growth 6.41%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 55.43%

10-year low 10-year high

P/B against its own 10 years 13.49%

10-year low 10-year high

EV/Sales against its own 10 years 43.45%

10-year low 10-year high

EV/FCF against its own 10 years 73.54%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	0.00	2.13
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	17,911	18,162	16,832	17,183
Receivables	2,527	1,638	1,105	273
Inventory	387	307	125	117
Other	309	241	206	213
	21,134	20,347	18,268	17,786

	2023	2024	2025	Q'26
Payables	383	462	605	752
ST’ Debt	30	43	59	67
Other	1,259	2,221	1,685	1,423
	2,241	2,730	2,424	2,266

Compound Annual Growth %

	10y	5y	3y
Sales	—	42.58%	(43.74%)
Cash Flow	—	0.00%	(66.96%)
Earnings	—	0.00%	0.00%
Book Value	—	69.23%	0.97%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	138	123	—	—	—
’25	193	296	1,775	983	3,247
’24	204	139	1,369	1,266	2,977
’23	1,371	183	974	1,605	4,133
’22	7,154	3,402	3,486	4,197	18,238
’21	2,470	6,396	7,178	6,407	22,451
’20	31	46	79	396	551

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(493)	15	—	—	—
’25	(822)	103	891	345	516
’24	(344)	1,755	(673)	(513)	225
’23	(727)	4,772	875	893	5,813
’22	4,545	3,936	4,359	1,465	14,305
’21	(375)	(121)	1,780	(232)	1,053
’20	(60)	(17)	(230)	292	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(583)	(44)	—	—	—
’25	(1,473)	18	828	301	(326)
’24	(493)	1,604	(770)	(605)	(263)
’23	(786)	4,434	712	691	5,050
’22	4,477	3,859	4,284	1,303	13,923
’21	(409)	(157)	1,733	(293)	874
’20	(70)	(36)	(255)	249	(112)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.46)	(3.77)	—	—	—
’25	(1.82)	(1.82)	(0.14)	(1.46)	(5.32)
’24	(1.42)	(3.62)	0.89	1.15	(3.00)
’23	2.20	(0.86)	0.73	2.05	4.15
’22	15.98	7.31	7.04	9.46	39.80
’21	5.29	12.98	14.56	13.93	46.89
’20	(0.26)	(0.42)	(1.03)	1.87	0.07

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	12.53	28.00	83.00	117.08	88.00	76.53	81.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	38.75	131.00	464.00	256.14	156.28	131.49	129.27
People
People	Employees	—	—	1,179	1,310	1,941	3,082	4,530	6,133	6,772	7,807
	Revenue/emp, $m	—	0.00	0.13	0.09	0.28	7.28	4.03	0.67	0.44	0.42
Income, $m
Income, $m	Revenue	—	69	151	122	551	22,451	18,238	4,133	2,977	3,247
	Gross margin, %	—	68.12	89.27	84.01	87.70	84.66	82.70	84.29	80.32	77.64
	EBT	—	(97)	(56)	(201)	(167)	17,801	13,648	1,284	(733)	(1,189)
	EBT margin, %	—	(140.58)	(37.36)	(165.25)	(30.23)	79.29	74.83	31.06	(24.63)	(36.61)
	Net income	—	0	(56)	(201)	(167)	17,801	13,648	1,284	(733)	(1,189)
	Depreciation	—	12	26	38	44	89	130	198	322	433
Per share, $
Per share, $	Revenue	—	7.67	0.79	0.58	2.34	92.01	74.96	17.18	12.38	13.43
	Earnings	—	(10.43)	(0.30)	(0.95)	0.07	49.91	40.87	4.19	(3.00)	(5.32)
	Cash flow	—	(6.56)	(0.36)	(1.05)	(0.07)	4.31	58.80	24.16	0.93	2.13
	Capex	—	0.00	(0.42)	(0.38)	(0.41)	(0.73)	(1.57)	(3.17)	(2.03)	(3.48)
	Free cash flow	—	(6.56)	(0.78)	(1.43)	(0.47)	3.58	57.23	20.99	(1.10)	(1.35)
	Book value	—	(6.56)	1.65	2.61	6.66	57.67	86.85	91.07	87.37	89.99
	Shares, m	—	9	191	211	235	244	243	241	240	242
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	509.50	5.19	3.59	27.07	0.00	0.00
	P/S	—	0.00	0.00	0.00	34.84	2.80	1.98	6.54	9.20	7.09
	P/B	—	6.61	6.61	15.73	12.25	4.47	1.71	1.23	1.30	1.06
	EV/Sales	—	0.00	0.00	0.00	32.54	2.71	1.18	2.26	3.19	2.00
	EV/FCF	—	0.00	0.00	0.00	(160.68)	69.54	1.55	1.85	(36.10)	(19.85)
Cash, $m
Cash, $m	Operating cash flow	—	(59)	(69)	(222)	(15)	1,053	14,305	5,813	225	516
	Capex	—	(65)	(79)	(80)	(96)	(178)	(382)	(764)	(488)	(842)
	Free cash flow	—	(59)	(148)	(302)	(112)	874	13,923	5,050	(263)	(326)
Balance, $m
Balance, $m	Working capital	—	35	381	473	1,212	13,713	19,988	18,893	17,617	15,844
	Total debt	—	62	64	79	274	357	224	237	275	303
	Net debt	—	(145)	(422)	(504)	(1,265)	(2,097)	(14,595)	(17,674)	(17,886)	(16,530)
	Shareholders’ equity	—	(59)	315	553	1,567	14,071	21,131	21,912	21,005	21,750
Returns, %
Returns, %	ROA	—	(16.22)	(14.71)	(24.10)	0.98	113.92	45.96	4.07	(2.92)	(5.22)
	ROIC	—	0.00	0.00	(262.39)	(19.47)	94.38	127.38	11.02	(28.51)	(19.03)
	ROE	—	(79.18)	(44.25)	(46.21)	1.64	155.73	56.47	4.68	(3.35)	(6.01)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%	Compare
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
INSM Insmed, Inc.	$21.7B	— (loss-making)	— (loss-making)	+296.11% (above 0%: growing)	n/m	+54.52% (above 0%: growing)	84.20%	(0.36%)	Compare
EXEL Exelixis, Inc.	$15.6B	18.8×	16.7×	+10.63% (above 0%: growing)	+25.00% (above 0%: growing)	+557.25% (above 0%: growing)	96.71%	39.51%	Compare
ASND Ascendis Pharma A/S	$14.9B	16.3×	13.0×	+119.88% (above 0%: growing)	n/m	+2,335.93% (above 0%: growing)	91.85%	64.98%	Compare
Median of peers	$22.8B	24.0×	18.9×	+31.29%	+7.87%	+103.67%	92.29%	26.11%

All 614 Biotechnology stocks →

BioNTech SE Sponsored ADR (BNTX) key facts

Concern: BioNTech SE Sponsored ADR reported a net loss of $1.2 billion, or a loss of $5.32 per share, for fiscal 2025.
Strength: BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
BioNTech SE Sponsored ADR (BNTX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, BNTX traded at $87.57, a market capitalization of $22.7 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7.3× sales.
Return on equity was −6.01% and debt-to-equity 0.02.
Its Piotroski F-score is 4 out of 9 for fiscal 2025.